Genta Incorporated announced that the European Patent Office intends to grant two key patents related to the company’s intellectual property position on Genasense® (oblimersen sodium) Injection. These two patents will provide protection for compositions, sequences, and pharmaceutical uses of Genasense and related compounds that attack Bcl-2, the molecular target of Genasense action.
“Genta’s patent estate related to Genasense is extensive, we have detailed plans for securing rapid approval in Europe with positive data this Fall,” commented Dr. Raymond P. Warrell, Jr., Genta’s Chief Executive Officer. “The majority of patients enrolled into the AGENDA trial, a Phase 3 trial of Genasense in melanoma that completed accrual earlier this month, originated from Europe. The extended market protection offered by these patents comes at an especially favorable time in the product’s lifecycle.”
Let us hear your thoughts below: